Corcept Therapeutics Incorporated
S&P 600
$112.79
-1.85%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Return on equity is moderate at 14.1%.
- Net profit margin is 13.1%.
- Current assets comfortably cover current liabilities (current ratio 2.92).
!Watch-points
- Return on capital employed is on the lower side at 6.2%.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreSafe zone
46.17
In Altman’s original study, companies in this range showed a low incidence of financial distress.
Piotroski F-ScoreModerate
4 / 7
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 7 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap$12.19B
Current Price$ 112.79
High / Low$ 126.38 / 28.66
Stock P/E250.64445
Book Value$ 5.96
Dividend Yield0%
ROCE6.20%
ROE14.12%
Current Ratio2.92
P/B Ratio17.246178
EPS$ 0.82
PAT Margin13.09%
Cash PAT$100.80M